Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery

Molecular Pharmaceutics

Volumn 6, Issue 4, 2009, Pages 1041-1051

  Gullotti, Emily ^a   Yeo, Yoon ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Activatable (activated) nanocarriers; Active targeting; Drug delivery; Nanocarriers; Passive targeting; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRIMER; DOXORUBICIN; IMMUNOLIPOSOME; LIPOSOME; MATRIX METALLOPROTEINASE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLY(DEXTRO,LEVO LACTIC CO GLYCOLIC ACID)POLY(ETHYLENE GLYCOL); POLY(EPSILONE CAPROLACTONE)POLY(ETHYL ETHYLENE PHOSPHATE); POLY(LACTIC ACID)POLY(ETHYLENE OXIDE); POLYMER; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ADVANCED CANCER; AREA UNDER THE CURVE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER TISSUE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG SELECTIVITY; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME SYNTHESIS; EXTRACELLULAR SPACE; HUMAN; KAPOSI SARCOMA; MELANOMA; MICELLE; NANOFABRICATION; NANOMEDICINE; NONHUMAN; OVARY CANCER; PASSIVE TRANSPORT; PH; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TARGET ORGAN;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 68249118615     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900090z     Document Type: Review

References (114)

1. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986, 46, 6387-6392. (Pubitemid 17221789)
2. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 2000, 65 (1-2), 271. (Pubitemid 30122932)
3. Yang, T.; Choi, M. K.; Cui, F. D.; Kim, J. S.; Chung, S. J.; Shim, C. K.; Kim, D. D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Controlled Release 2007, 120 (3), 169-177.
4. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K. L.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66 (13), 6732-6740.
5. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z. X.; Hong, K. L.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65 (24), 11631-11638.
6. Wang, Y. Z.; Yu, L.; Han, L. M.; Sha, X. Y.; Fang, X. L. Difunctional Pluronic copolymer micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm. 2007, 337 (1-2), 63-73.
7. Dagar, S.; Krishnadas, A.; Rubinstein, I.; Blend, M. J.; Onyuksel, H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J. Controlled Release 2003, 91 (1-2), 123-133. (Pubitemid 37288883)
8. Matsumura, Y. Polymeric Micellar Delivery Systems in Oncology. Jpn. J. Clin. Oncol. 2008, 38 (12), 793-802.
9. Hamidreza Montazeri, A.; Shahin, M.; Brocks, D. R.; Lavasanifar, A. Disposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery. Clin. Pharmacokinet. 2008, 47, 619-634.
10. Yokoyama, M. Drug targeting with nano-sized carrier systems. J. Artif. Organs 2005, 8 (2), 77-84. (Pubitemid 41139586)
11. Uhrich, K. E.; Cannizzaro, S. M.; Langer, R. S.; Shakesheff, K. M. Polymeric systems for controlled drug release. Chem. Rev. 1999, 99 (11), 3181-3198. (Pubitemid 129583051)
12. Soussan, E.; Cassel, S.; Blanzat, M.; Rico-Lattes, I. Drug Delivery by Soft Matter: Matrix and Vesicular Carriers. Angew. Chem., Int. Ed. 2009, 48 (2), 274-288.
13. Allen, T. M.; Cullis, P. R. Drug Delivery Systems: Entering the Mainstream. Science 2004, 303 (5665), 1818-1822. (Pubitemid 38374867)
14. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and Imaging. AAPS J. 2007, 9 (2), E128-E147.
15. Pridgen, E. M.; Langer, R.; Farokhzad, O. C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007, 2 (5), 669-680. (Pubitemid 350268246)
16. van Vlerken, L.; Vyas, T.; Amiji, M. Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery. Pharm. Res. 2007, 24 (8), 1405-1414.
17. Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications. Angew. Chem., Int. Ed. 2006, 45 (8), 1198-1215.
18. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nano 2007, 2 (12), 751-760. (Pubitemid 350223348)
19. Cheng, Y. Y.; Wang, J. R.; Rao, T. L.; He, X. X.; Xu, T. W. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front. Biosci. 2008, 13, 1447-1471.
20. Li, C.; Wallace, S. Polymer-drug conjugates: Recent development in clinical oncology. Adv. Drug Delivery Rev. 2008, 60 (8), 886-898.
21. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Controlled Release 2008, 126 (3), 187-204.
22. Parveen, S.; Sahoo, S. K. Polymeric nanoparticles for cancer therapy. J. Drug Targeting 2008, 16 (2), 108-123.
23. Agarwal, A.; Saraf, S.; Asthana, A.; Gupta, U.; Gajbhiye, V.; Jain, N. K. Ligand based dendritic systems for tumor targeting. Int. J. Pharm. 2008, 350 (1-2), 3-13.
24. Cho, K. J.; Wang, X.; Nie, S. M.; Chen, Z.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14 (5), 1310-1316.
25. Bremer, E.; de Bruyn, M.; Wajant, H.; Helfrich, W. Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family. Curr. Drug Targets 2009, 10 (2), 94-103.
26. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Delivery Rev. 2008, 60 (15), 1615-1626.
27. Hervella, P.; Lozano, V.; Garcia-Fuentes, M. Nanomedicine: New Challenges and Opportunities in Cancer Therapy. J. Biomed. Nanotechnol. 2008, 4 (3), 276-292.
28. Huwyler, J.; Drewe, J.; Krahenbuhl, S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomed. 2008, 3 (1), 21-29.
29. Igarashi, E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol. Appl. Pharmacol. 2008, 229 (1), 121-134.
30. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34 (7), 592-602.
31. Mondon, K.; Gurny, R.; Moller, M. Colloidal Drug Delivery Systems - Recent Advances With Polymeric Micelles. Chimia 2008, 62 (10), 832-840.
32. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207. (Pubitemid 32520323)
33. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Targeting 2007, 15 (7-8), 457-464 (Pubitemid 47209047)
34. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55 (17), 3752-3756.
35. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Delivery Rev. 2002, 54 (5), 631-651.
36. Gabizon, A. A.; Shmeeda, H.; Zalipsky, S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 2006, 16 (3), 175-183. (Pubitemid 44358991)
37. Lee, E. S.; Oh, K. T.; Kim, D.; Youn, Y. S.; Bae, Y. H. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly (ethylene glycol)-b-poly(L-histidine). J. Controlled Release 2007, 123 (1), 19-26.
38. Caliceti, P.; Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 2003, 55 (10), 1261-1277.
39. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Mol. Pharmaceutics 2008, 5 (4), 505-515.
40. Guasch, A.; Deen, W. M.; Myers, B. D. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J. Clin. Invest. 1993, 92 (5), 2274-2282. (Pubitemid 23333533)
41. Rennke, H. G.; Cotran, R. S.; Venkatachalam, M. A. Role of molecular charge in glomerular permeability. Tracer studies with cationized ferritins. J. Cell Biol. 1975, 67 (3), 638-646.
42. Owens, D. E.; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307 (1), 93-102.
43. Howard, M. D.; Jay, M.; Dziublal, T. D.; Lu, X. L. PEGylation of nanocarrier drug delivery systems: State of the art. J. Biomed. Nanotechnol. 2008, 4 (2), 133-148.
44. Oku, N.; Tokudome, Y.; Asai, T.; Tsukada, H. Evaluation of Drug Targeting Strategies and Liposomal Trafficking. Curr. Pharm. Des. 2000, 6, 1669-1691. (Pubitemid 30765418)
45. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies. Clin. Pharmacokinet. 2003, 42 (5), 419-436. (Pubitemid 36649037)
46. Gabizon, A. A. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19 (4), 424-436.
47. Colbern, G. T.; Hiller, A. J.; Musterer, R. S.; Pegg, E.; Henderson, I. C.; Working, P. K. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J. Liposome Res. 1999, 9 (4), 523-538.
48. Bae, Y. H. Drug targeting and tumor heterogeneity. J. Controlled Release 2009, 133 (1), 2-3.
49. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4607-4612.
50. Heldin, C.-H.; Rubin, K.; Pietras, K.; Ostman, A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4, 806-813. (Pubitemid 39331152)
51. Netti, P. A.; Roberge, S.; Boucher, Y.; Baxter, L. T.; Jain, R. K. Effect of Transvascular Fluid Exchange on Pressure-Flow Relationship in Tumors: A Proposed Mechanism for Tumor Blood Flow Heterogeneity. Microvasc. Res. 1996, 52 (1), 27-46.
52. Mishra, S.; Webster, P.; Davis, M. E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 2004, 83 (3), 97-111.
53. Gryparis, E. C.; Hatziapostolou, M.; Papadimitriou, E.; Avgoustakis, K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm. 2007, 67 (1), 1-8. (Pubitemid 46991325)
54. Romberg, B.; Hennink, W.; Storm, G. Sheddable Coatings for Long-Circulating Nanoparticles. Pharm. Res. 2008, 25 (1), 55-71.
55. Hong, R. L.; Huang, C. J.; Tseng, Y. L.; Pang, V. F.; Chen, S. T.; Liu, J. J.; Chang, F. H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial. Clin. Cancer Res. 1999, 5 (11), 3645-3652.
56. Kaasgaard, T.; Mouritsen, O. G.; Jørgensen, K. Screening effect of PEG on avidin binding to liposome surface receptors. Int. J. Pharm. 2001, 214 (1-2), 63-65. (Pubitemid 32244079)
57. Hatakeyama, H.; Akita, H.; Kogure, K.; Oishi, M.; Nagasaki, Y.; Kihira, Y.; Ueno, M.; Kobayashi, H.; Kikuchi, H.; Harashima, H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007, 14 (1), 68-77. (Pubitemid 44942867)
58. Lavasanifar, A.; Samuel, J.; Kwon, G. S. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv. Drug Delivery Rev. 2002, 54 (2), 169-190.
59. Ozawa, M. G.; Zurita, A. J.; Dias-Neto, E.; Nunes, D. N.; Sidman, R. L.; Gelovani, J. G.; Arap, W.; Pasqualini, R. Beyond Receptor Expression Levels: The Relevance of Target Accessibility in Ligand-Directed Pharmacodelivery Systems. Trends Cardiovasc. Med. 2008, 18 (4), 126-133.
60. Voss, S. D.; Smith, S. V.; DiBartolo, N.; McIntosh, L. J.; Cyr, E. M.; Bonab, A. A.; Dearling, J. L. J.; Carter, E. A.; Fischman, A. J.; Treves, S. T.; Gillies, S. D.; Sargeson, A. M.; Huston, J. S.; Packard, A. B. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (44), 17489-17493. (Pubitemid 350219865)
61. Mandler, R.; Kobayashi, H.; Hinson, E. R.; Brechbiel, M. W.; Waldmann, T. A. Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity. Cancer Res. 2004, 64 (4), 1460-1467.
62. Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases. Acc. Chem. Res. 2007, 41 (1), 120-129.
63. ElBayoumi, T. A.; Torchilin, V. P. Tumor-Specific Anti-Nucleosome Antibody Improves Therapeutic Efficacy of Doxorubicin-Loaded Long-Circulating Liposomes against Primary and Metastatic Tumor in Mice. Mol. Pharmaceutics 2009, 6 (1), 246-254.
64. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (39), 15549-15554.
65. Gabizon, A.; Horowitz, A. T.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In vivo fate of folate-targeted polyethyleneglycol liposomes in tumor-bearing mice. Clin. Cancer Res. 2003, 9 (17), 6551-6559. (Pubitemid 38031844)
66. Xiong, X. B.; Huang, Y.; Lu, W. L.; Zhang, X.; Zhang, H.; Nagai, T.; Zhang, Q. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci. 2005, 94 (8), 1782-1793. (Pubitemid 41360872)
67. Xiong, X. B.; Huang, Y.; Lu, W. L.; Zhang, H.; Zhang, X.; Zhang, Q. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 2005, 22 (6), 933-939. (Pubitemid 40898103)
68. ElBayoumi, T. A.; Torchilin, V. P. Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody. Clin. Cancer Res. 2009, 15 (6), 1973-1980.
69. Hu, Z. Y.; Luo, F.; Pan, Y. F.; Hou, C.; Ren, L. F.; Chen, J. J.; Wang, J. W.; Zhang, Y. D. Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. Part A 2008, 85A (3), 797-807.
70. Yang, T.; Choi, M. K.; Cui, F. D.; Lee, S. J.; Chung, S. J.; Shim, C. K.; Kim, D. D. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm. Res. 2007, 24 (12), 2402-2411.
71. Yoo, H. S.; Park, T. G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Controlled Release 2004, 96 (2), 273-283.
72. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6315-6320.
73. Lu, Y. J.; Xu, L. C.; Parker, N.; Westrick, E.; Reddy, J. A.; Vetzel, M.; Low, P. S.; Leamon, C. P. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Mol. Cancer Ther. 2006, 5 (12), 3258-3267.
74. Gabizon, A.; Shmeeda, H.; Horowitz, A. T.; Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Delivery Rev. 2004, 56 (8), 1177-1192. (Pubitemid 38496514)
75. Farokhzad, O. C.; Jon, S. Y.; Khadelmhosseini, A.; Tran, T. N. T.; LaVan, D. A.; Langer, R. Nanopartide-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 2004, 64 (21), 7668-7672. (Pubitemid 39446893)
76. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (7), 2586-2591.
77. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28 (5), 869-876. (Pubitemid 44667020)
78. Gerweck, L. E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res. 1996, 56 (6), 1194-1198. (Pubitemid 26080953)
79. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2 (3), 161-174. (Pubitemid 37328786)
80. Montcourrier, P.; Silver, I.; Farnoud, R.; Bird, I.; Rochefort, H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin. Exp. Metastasis 1997, 15 (4), 382-392. (Pubitemid 27285811)
81. Swallow, C. J.; Grinstein, S.; Rotstein, O. D. A vacuolar type H(+)-ATPase regulates cytoplasmic pH in murine macrophages. J. Biol. Chem. 1990, 265 (13), 7645-7654. (Pubitemid 20162517)
82. Mok, H.; Bae, K. H.; Ahn, C.-H.; Park, T. G. PEGylated and MMP-2 Specifically DePEGylated Quantum Dots: Comparative Evaluation of Cellular Uptake. Langmuir 2009, 25 (3), 1645-1650.
83. Lee, S.; Park, K.; Lee, S.-Y.; Ryu, J. H.; Park, J. W.; Ahn, H. J.; Kwon, I. C.; Youn, I.-C.; Kim, K.; Choi, K. Dark Quenched Matrix Metalloproteinase Fluorogenic Probe for Imaging Osteoarthritis Development in Vivo. Bioconjugate Chem. 2008, 19 (9), 1743-1747.
84. Scherer, R. L.; VanSaun, M. N.; McIntyre, J. O.; Matrisian, L. M. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol. Imaging 2008, 7 (3), 118-131.
85. Wunder, A.; Tung, C. H.; Muller-Ladner, U.; Weissleder, R.; Mahmood, U. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum. 2004, 50 (8), 2459-2465. (Pubitemid 39062705)
86. Weissleder, R.; Tung, C. H.; Mahmood, U.; Bogdanov, A., Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 1999, 17 (4), 375-378.
87. Lee, E. S.; Gao, Z.; Bae, Y. H. Recent progress in tumor pH targeting nanotechnology. J. Controlled Release 2008, 132 (3), 164-170.
88. Lee, E. S.; Gao, Z.; Kim, D.; Park, K.; Kwon, I. C.; Bae, Y. H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Controlled Release 2008, 129 (3), 228-236.
89. Ko, J.; Park, K.; Kim, Y. S.; Kim, M. S.; Han, J. K.; Kim, K.; Park, R. W.; Kim, I. S.; Song, H. K.; Lee, D. S.; Kwon, I. C. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (beta-amino ester) block copolymer micelles for cancer therapy. J. Controlled Release 2007, 123 (2), 109-115.
90. Min, K. H.; Park, K.; Kim, Y. S.; Bae, S. M.; Lee, S.; Jo, H. G.; Park, R. W.; Kim, I. S.; Jeong, S. Y.; Kim, K.; Kwon, I. C. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Controlled Release 2008, 127 (3), 208-218.
91. Cho, Y. W.; Park, S. A.; Han, T. H.; Son, D. H.; Park, J. S.; Oh, S. J.; Moon, D. H.; Cho, K. J.; Ahn, C. H.; Byun, Y.; Kim, I. S.; Kwon, I. C.; Kim, S. Y. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: Mechanisms, key factors, and their implications. Biomaterials 2007, 28 (6), 1236-1247.
92. Liu, W. G.; Sun, S. J.; Cao, Z. Q.; Xin, Z.; Yao, K. D.; Lu, W. W.; Luk, K. D. K. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials 2005, 26 (15), 2705-2711. (Pubitemid 39600723)
93. Sawant, R. M.; Hurley, J. P.; Salmaso, S.; Kale, A.; Tolcheva, E.; Levchenko, T. S.; Torchilin, V. P. "SMART" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjugate Chem. 2006, 17 (4), 943-949. (Pubitemid 44162612)
94. Sethuraman, V. A.; Bae, Y. H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Controlled Release 2007, 118 (2), 216-224.
95. Sethuraman, V.; Lee, M.; Bae, Y. A Biodegradable pH-sensitive Micelle System for Targeting Acidic Solid Tumors. Pharm. Res. 2008, 25 (3), 657-666.
96. Lee, E. S.; Na, K.; Bae, Y. H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 2005, 5 (2), 325-329.
97. Chau, Y.; Tan, F. E.; Langer, R. Synthesis and Characterization of Dextran-Peptide-Methotrexate Conjugates for Tumor Targeting via Mediation by Matrix Metalloproteinase II and Matrix Metalloproteinase IX. Bioconjugate Chem. 2004, 15 (4), 931-941.
98. Chau, Y.; Dang, N. M.; Tan, F. E.; Langer, R. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. J. Pharm. Sci. 2006, 95 (3), 542-551.
99. Chau, Y.; Padera, R. F.; Dang, N. M.; Langer, R. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int. J. Cancer 2006, 118 (6), 1519-1526. (Pubitemid 43306541)
100. Chen, H.; Kim, S.; He, W.; Wang, H.; Low, P. S.; Park, K.; Cheng, J. X. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging. Langmuir 2008, 24 (10), 5213-5217.
101. Ooya, T.; Choi, H. S.; Yamashita, A.; Yui, N.; Sugaya, Y.; Kano, A.; Maruyama, A.; Akita, H.; Ito, R.; Kogure, K.; Harashima, H. Biocleavable Polyrotaxane-Plasmid DNA Polyplex for Enhanced Gene Delivery. J. Am. Chem. Soc. 2006, 128 (12), 3852-3853.
102. Breunig, M.; Lungwitz, U.; Liebl, R.; Goepferich, A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc. Natl. Acad. Sci. U.S.A. 2007, 14454-14459. (Pubitemid 350003282)
103. Breunig, M.; Hozsa, C.; Lungwitz, U.; Watanabe, K.; Umeda, I.; Kato, H.; Goepferich, A. Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: Disulfide bonds boost intracellular release of the cargo. J. Controlled Release 2008, 130, 57-63.
104. Neu, M.; Sitterberg, J.; Bakowsky, U.; Kissel, T. Stabilized Nanocarriers for Plasmids Based Upon Cross-linked Poly(ethylene imine). Biomacromolecules 2006, 7 (12), 3428-3438. (Pubitemid 46111798)
105. Bae, Y.; Nishiyama, N.; Fukushima, S.; Koyama, H.; Yasuhiro, M.; Kataoka, K. Preparation and Biological Characterization of Polymeric Micelle Drug Carriers with Intracellular pH-Triggered Drug Release Property: Tumor Permeability, Controlled Subcellular Drug Distribution, and Enhanced in Vivo Antitumor Efficacy. Bioconjugate Chem. 2005, 16 (1), 122-130.
106. Kakizawa, Y.; Harada, A.; Kataoka, K. Environment-Sensitive Stabilization of Core-Shell Structured Polyion Complex Micelle by Reversible Cross-Linking of the Core through Disulfide Bond. J. Am. Chem. Soc. 1999, 121 (48), 11247-11248.
107. Lukyanov, A. N.; Elbayoumi, T. A.; Chakilam, A. R.; Torchilin, V. P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Controlled Release 2004, 100 (1), 135-144.
108. Elbayoumi, T. A.; Torchilin, V. P. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 2007, 32 (3), 159-168.
109. Park, J. W.; Hong, K. L.; Kirpotin, D. B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Moore, D.; Papahadjopoulos, D.; Benz, C. C. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8 (4), 1172-1181.
110. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Controlled Release 2007, 120 (1-2), 18-26. (Pubitemid 46874614)
111. Kim, S. H.; Jeong, J. H.; Chun, K. W.; Park, T. G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005, 21 (19), 8852-8857.
112. Zhang, L.; Chan, J. M.; Gu, F. X.; Rhee, J.-W.; Wang, A. Z.; Radovic-Moreno, A. F.; Alexis, F.; Langer, R.; Farokhzad, O. C. Self-Assembled Lipid-Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. ACS Nano 2008, 2 (8), 1696-1702.
113. Wang, Y. C.; Liu, X. Q.; Sun, T. M.; Xiong, M. H.; Wang, J. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J. Controlled Release 2008, 128 (1), 32-40.
114. Esmaeili, F.; Ghahremani, M. H.; Ostad, S. N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M. R.; Amini, M.; Dinarvand, R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Targeting 2008, 16 (5), 415-423. (Pubitemid 351935739)